AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioAffinity Technologies Presents Research at CHEST 2025 Supporting CyPath Lung Processing Methods
ByAinvest
Monday, Oct 20, 2025 5:35 pm ET1min read
will present research at CHEST 2025, supporting the methods used for collecting and transporting patient samples for analysis by their noninvasive CyPath® Lung test for early-stage lung cancer detection. The study aims to demonstrate the scientific rigor applied to the CyPath® Lung process, which has shown accurate and reliable results. The presentation will take place at Booth #2242 during the conference.
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company specializing in noninvasive diagnostics for lung cancer and other lung diseases, will present research at the upcoming CHEST 2025 conference. The study aims to validate the methods used for collecting and transporting patient samples for analysis by the company’s CyPath® Lung test, which is designed to detect early-stage lung cancer.
The presentation, titled "The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests," will be delivered by Rossella Titone, PhD, project manager for product development at bioAffinity Technologies. The presentation will take place on October 22, 2025, at 10:20 a.m. at poster board #4324 during the annual meeting of the American College of Chest Physicians.
The CyPath® Lung test uses advanced flow cytometry and artificial intelligence to identify cell populations in patient sputum that indicate malignancy. The study presented at CHEST 2025 will focus on the protocols for handling clinical samples collected at home by patients and returned to the laboratory for processing. According to the company, physicians usually receive results within two days.
The research is crucial as it supports the protocols used for handling clinical samples, ensuring the reliability and accuracy of the CyPath® Lung test. The test has demonstrated high sensitivity, specificity, and accuracy in detecting lung cancer, with 92% sensitivity, 87% specificity, and 88% accuracy in clinical studies, according to a MarketScreener report
.The presentation at CHEST 2025 is part of bioAffinity Technologies’ ongoing efforts to advance the CyPath® Lung technology and improve patient outcomes. The company expects to engage with physicians and healthcare professionals at the conference to discuss the potential benefits of the test and its role in early-stage lung cancer detection.
For more information about bioAffinity Technologies and the CyPath® Lung test, visit www.bioaffinitytech.com.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet